Hrishi Srinagesh

MD/MSCR. Stanford Hematology Fellow by way of Stanford Internal Medicine by way of Icahn School of Medicine at Mount Sinai and Williams College.

[Hrishi Srinagesh @HSrinagesh]

IL-10 mediated suppression of IL-6 via SOCS3 may further drive HLH-like toxicities and the IL-10:IL-6 ratio may help predict this toxicity as recently shown by the French HLH group https://t.co/rPPQvMhItf

[Hrishi Srinagesh @HSrinagesh]

More evidence that IL-10 is a key mediator of CAR22 activity from a nice UPenn study https://t.co/QuZRWsY096

[Hrishi Srinagesh @HSrinagesh]

IL-10 modulating immune synapse formation is an intriguing mechanism of increasing IFNg production and may help explain its role in IEC-HS.

[Hrishi Srinagesh @HSrinagesh]

It was a real pleasure to talk about our latest work from the ROCCA consortium! Please check out to learn more about how prior blinatumomab affects brexu-cel outcomes in adults with B-ALL in the real-world setting.

[Blood Journals Portfolio @BloodPortfolio]

New Blood Podcast episode! Dr. Laurie Sehn interviews Drs. Shengwen Calvin Li of @UCIrvine and Hrishi K. Srinagesh of @Stanford on their latest articles published in Blood. From thrombocytopenia to B-ALL, listen to the conversation here:
https://t.co/Qt5SvnIZo1

[Hrishi Srinagesh @HSrinagesh]

Appreciate the insightful editorial from Joseph Rocco and Nirali Shah from NCI: https://t.co/24YCzpepMv

[Hrishi Srinagesh @HSrinagesh]

Please check out our latest paper on clinical and biomarker features of IEC-HS! We identified a cytokine signature temporally associated with CAR22-related IEC-HS yielding clues into the pathophysiology of this emerging CAR-T related toxicity.

[Blood Cancer Discovery @BCD_AACR]

Join Matthew Frank as he discusses #CARTcell therapy approaches for B-cell leukemia and lymphoma and check out his recent paper on immune effector cell–associated hemophagocytic lymphohistiocytosis–like syndrome. #AACR26 #CARTcell #celltherapy https://t.co/sUZC9HUSn1

[Hrishi Srinagesh @HSrinagesh]

This signature includes IFNg-related cytokines and IL18, recapitulating the important work from NCI on IEC-HS. We also identify associations with cytokines involved in cell death signaling like TNFa and sFAS among others.

[ASTCT @ASTCT]

Be sure to catch James Ferrara, MD, DSc, as he presents the prestigious E. Donnall Thomas Lecture at #Tandem26. His talk will focus on the immunology of allogeneic BMT and its major complication, GVHD. Find the details in the Tandem Meetings News: https://t.co/dqZtRXfGBq

[Blood Journals Portfolio @BloodPortfolio]

Combining CAR-T cells targeting CD19 & CD22 with a recombinant, polymer-conjugated IL15 receptor agonist (NKTR-255) was safe and feasible. https://t.co/EPkQHGchPG #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia #transplantation

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma https://t.co/AsAghi5Avv @HSrinagesh

[Lymphoma Hub @lymphomahub]

CONGRESS|#EHA2023 Matthew Frank @StanfordMed discusses the safety and efficacy of CD22 CART therapy in pts with LBCL who have relapsed after CD19 CART therapy. The ORR and CR rates were 68% and 53%, respectively #lymphoma #lymsm #medicalcongress

[Lymphoma Hub @lymphomahub]

What are the guidelines to manage the newly defined CAR T-cell therapy-related HLH-like syndrome?
Check out our summary here 👉 https://t.co/yAhzPKTWGV.
#lymsm

[GvHD Hub @gvhd_hub]

CONGRESS #EBMT23 | John Levine @MountSinaiNYC discusses risk assessment in acute #GvHD in this educational session with a focus on biomarkers. He states that the best #GvHD biomarkers quantify damage to the GI tract (e.g. ST2+Reg3a) the organ most resistant to treatment #bmtsm

[GvHD Hub @gvhd_hub]

CONGRESS #EBMT23 | James Ferrara @MountSinaiNYC describes the use of a serum biomarker & clinical response 2 weeks after treatment as a composite endpoint. N = 1,138. This combo correctly reclassifies 1/2 of clinical NRs as late responders who have excellent OS. #GvHD #bmtsm

[Elena Vasti @ecvasti]

WOW! @StanfordMedRes residents FEARLESSLY going up against a derm differential presented masterfully by the one and only PGY3 @ATarimala! This was the story of a middle aged women with diffuse blistering rash, found to have TB induced hypersensitivity!

[Hrishi Srinagesh @HSrinagesh]

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin | Blood Advances | American Society of Hematology https://t.co/C4HVHTdCtE

[Hrishi Srinagesh @HSrinagesh]

@achyut_patil_ @VAPaloAlto @StanfordMedRes @kevn_li So glad you were our fearless leader!

[Hrishi Srinagesh @HSrinagesh]

@Poietic_Justice @IcahnMountSinai @danleisman @keithsigelmd Congrats to you too Lukas!